000513 丽珠集团
已收盘 07-11 15:00:00
资讯
新帖
简况
每周股票复盘:丽珠集团(000513)购回11,318,855股A股拟注销
证券之星 · 07-05
每周股票复盘:丽珠集团(000513)购回11,318,855股A股拟注销
丽珠集团:公司始终基于科学价值、临床需求和市场潜力
证券之星 · 07-02
丽珠集团:公司始终基于科学价值、临床需求和市场潜力
丽珠集团收盘上涨1.42%,滚动市盈率15.81倍,总市值330.45亿元
金融界 · 07-01
丽珠集团收盘上涨1.42%,滚动市盈率15.81倍,总市值330.45亿元
丽珠集团:研发投入达10.4亿元,聚焦多领域创新布局
证券之星 · 06-30
丽珠集团:研发投入达10.4亿元,聚焦多领域创新布局
丽珠集团新提交1件商标注册申请
证券之星 · 06-27
丽珠集团新提交1件商标注册申请
精准医疗概念盘中拉升,丽珠集团涨2.98%
市场透视 · 06-19
精准医疗概念盘中拉升,丽珠集团涨2.98%
每周股票复盘:丽珠集团(000513)研发管线多领域推进,BD战略助力国际化
证券之星 · 05-31
每周股票复盘:丽珠集团(000513)研发管线多领域推进,BD战略助力国际化
丽珠集团丽珠制药厂申请II类会议
金融界 · 05-27
丽珠集团丽珠制药厂申请II类会议
丽珠集团:5月26日接受机构调研,国联证券、华泰证券等多家机构参与
证券之星 · 05-27
丽珠集团:5月26日接受机构调研,国联证券、华泰证券等多家机构参与
丽珠集团:公司中药板块预计将实现稳健恢复性增长
E公司 · 05-26
丽珠集团:公司中药板块预计将实现稳健恢复性增长
每周股票复盘:丽珠集团(000513)拟15.87亿收购越南IMP公司64.81%股权
证券之星 · 05-24
每周股票复盘:丽珠集团(000513)拟15.87亿收购越南IMP公司64.81%股权
健康元(600380.SH):控股子公司丽珠集团拟收购越南IMP公司股权
格隆汇 · 05-22
健康元(600380.SH):控股子公司丽珠集团拟收购越南IMP公司股权
丽珠集团最新公告:拟15.87亿元收购越南IMP公司64.81%股份
证券之星 · 05-22
丽珠集团最新公告:拟15.87亿元收购越南IMP公司64.81%股份
丽珠集团(000513.SZ)拟收购越南IMP公司64.81%股权 交易价格约15.87亿元
智通财经 · 05-22
丽珠集团(000513.SZ)拟收购越南IMP公司64.81%股权 交易价格约15.87亿元
丽珠集团刘宁:累计投入超4亿用于节能减排及设备改造 在慢病防治、普惠医疗等领域公益性捐赠累计7000万
新浪财经 · 05-19
丽珠集团刘宁:累计投入超4亿用于节能减排及设备改造 在慢病防治、普惠医疗等领域公益性捐赠累计7000万
丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元
智通财经 · 05-06
丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元
丽珠集团:4月29日接受机构调研,国信证券参与
证券之星 · 04-30
丽珠集团:4月29日接受机构调研,国信证券参与
丽珠集团(000513.SZ)发布一季度业绩,归母净利润6.37亿元,同比增长4.75%
智通财经 · 04-23
丽珠集团(000513.SZ)发布一季度业绩,归母净利润6.37亿元,同比增长4.75%
【丽珠集团:副总裁杨代宏因工作调整原因辞职】丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。
金融界 · 04-23
【丽珠集团:副总裁杨代宏因工作调整原因辞职】丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。
丽珠集团:公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇
证券之星 · 04-21
丽珠集团:公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇
加载更多
公司概况
公司名称:
丽珠医药集团股份有限公司
所属行业:
医药制造业
上市日期:
1993-10-28
主营业务:
丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是注射用醋酸亮丙瑞林微球(贝依)、注射用尿促卵泡素(丽申宝)、注射用尿促性素(乐宝得)、艾普拉唑肠溶片及注射用艾普拉唑钠(壹丽安)、枸橼酸铋钾系列产品(丽珠得乐)、维三联(枸橼酸铋钾片/替硝唑片/克拉霉素片)、马来酸氟伏沙明片(瑞必乐)、盐酸哌罗匹隆片(康尔汀)、参芪扶正注射液、抗病毒颗粒。
发行价格:
6.38
{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":36.96,"timestamp":1752217380000,"preClose":37.33,"halted":0,"volume":7925717,"delay":0,"changeRate":-0.0099,"floatShares":584000000,"shares":903999999,"eps":2.3117,"marketStatus":"已收盘","change":-0.37,"latestTime":"07-11 15:00:00","open":37.29,"high":37.39,"low":36.8,"amount":294000000,"amplitude":0.0158,"askPrice":36.97,"askSize":1,"bidPrice":36.96,"bidSize":115,"shortable":0,"etf":0,"ttmEps":2.3117,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752456600000},"marketStatusCode":5,"adr":0,"adjPreClose":37.33,"symbolType":"stock","openAndCloseTimeList":[[1752197400000,1752204600000],[1752210000000,1752217200000]],"highLimit":41.06,"lowLimit":33.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":904100430,"isCdr":false,"pbRate":2.38,"roa":"--","peRate":15.988234,"roe":"4.55%","epsLYR":2.24,"committee":0.365079,"marketValue":33416000000,"turnoverRate":0.0136,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-07-14。","hkstockBrief":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":29.65,"timestamp":1752221283027,"preClose":29.7,"halted":0,"volume":1306000,"delay":0,"premium":"-26.69"},"floatMarketCap":21597000000},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2549424253","title":"每周股票复盘:丽珠集团(000513)购回11,318,855股A股拟注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2549424253","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549424253?lang=zh_cn&edition=full","pubTime":"2025-07-06 03:34","pubTimestamp":1751744052,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘,丽珠集团报收于36.34元,较上周的36.34元上涨0.0%。本周关注点公司公告汇总:丽珠集团购回11,318,855股A股拟注销但尚未注销公司公告汇总丽珠医药集团股份有限公司于2025年7月1日提交了截至2025年6月30日的证券变动月报表给香港交易及结算所有限公司。值得注意的是,在2024年12月24日,公司购回了11,318,855股A股,这些股份拟注销但截至本月底尚未注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","399300","BK0187","BK0188","159982","000513"],"gpt_icon":0},{"id":"2548603498","title":"丽珠集团:公司始终基于科学价值、临床需求和市场潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2548603498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548603498?lang=zh_cn&edition=full","pubTime":"2025-07-02 17:24","pubTimestamp":1751448246,"startTime":"0","endTime":"0","summary":"证券之星消息,丽珠集团(000513)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问:建议贵司加大小核酸药物及干细胞领域投入力度!砍掉一些没有价值及竞争力的品种丽珠集团回复:尊敬的投资者,您好!感谢您对公司研发方向的关注。公司始终基于科学价值、临床需求和市场潜力,通过定期的系统化流程审视研发管线布局并动态优化资源分配,确保聚焦于最具前景的核心领域,以驱动可持续增长及提升长期竞争力。具体研发策略及进展请关注公司定期报告与公告,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200028067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0188","000513","BK0239"],"gpt_icon":0},{"id":"2548807631","title":"丽珠集团收盘上涨1.42%,滚动市盈率15.81倍,总市值330.45亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548807631","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548807631?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:11","pubTimestamp":1751357474,"startTime":"0","endTime":"0","summary":"7月1日,丽珠集团今日收盘36.55元,上涨1.42%,滚动市盈率PE达到15.81倍,创13天以来新低,总市值330.45亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均54.81倍,行业中值32.58倍,丽珠集团排名第48位。资金流向方面,7月1日,丽珠集团主力资金净流入966.62万元,近5日总体呈流入状态,5日共流入3781.18万元。最新一期业绩显示,2025年一季报,公司实现营业收入31.81亿元,同比-1.92%;净利润6.37亿元,同比4.75%,销售毛利率64.96%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/01161151411445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","BK0239","BK0187","BK0188","000513"],"gpt_icon":0},{"id":"2547057195","title":"丽珠集团:研发投入达10.4亿元,聚焦多领域创新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2547057195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547057195?lang=zh_cn&edition=full","pubTime":"2025-06-30 15:27","pubTimestamp":1751268435,"startTime":"0","endTime":"0","summary":"证券之星消息,丽珠集团06月30日在投资者关系平台上答复投资者关心的问题。丽珠集团始终将研发创新作为核心战略,2024年,公司研发投入达10.4亿元,占营收的8.8%。公司研发一方面聚焦于消化道、辅助生殖和精神神经等传统优势领域,持续完善产品布局及治疗方案;另一方面逐步扩展至代谢、心脑血管等慢性疾病领域,积极探索新机制和新靶点,丰富微球和重组蛋白疫苗等技术平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025063000014576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0187","BK0188","000513"],"gpt_icon":0},{"id":"2546572419","title":"丽珠集团新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2546572419","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546572419?lang=zh_cn&edition=full","pubTime":"2025-06-28 05:29","pubTimestamp":1751059773,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日丽珠医药集团股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来丽珠医药集团股份有限公司新申请注册商标10件,截止目前公司共持有注册商标1152件,另有66件商标尚在注册申请中。结合公司2024年年报财务数据,2024年公司在研发方面投入了10.33亿元,同比减22.58%。数据来源:天眼查APP以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062800005502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0187","000513","BK0028"],"gpt_icon":0},{"id":"2544187137","title":"精准医疗概念盘中拉升,丽珠集团涨2.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544187137","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544187137?lang=zh_cn&edition=full","pubTime":"2025-06-19 09:37","pubTimestamp":1750297040,"startTime":"0","endTime":"0","summary":"06月19日,精准医疗概念盘中拉升,截至09点37分,精准医疗概念整体指数上涨0.61%,报964.450点。从个股上来看,该概念的成分股中,丽珠集团涨2.98%,DR奕瑞科、西陇科学、贝达药业涨幅居前。从资金上来看,截止发稿,精准医疗概念主力净流入为-1772.74万,其中药明康德受到资金热捧,主力净流入627.37万;拉长时间线来看,该板块近20日主力资金净流入-43.91亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619093720a4b190c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619093720a4b190c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK0188","BK0239","LU1997245094.SGD","LU2495084118.USD","BK0187","LU1997245177.USD","LU2328871848.SGD","603259","BK0028","LU0456842615.SGD","LU1997244956.HKD","LU2488822045.USD","000513","BK0216"],"gpt_icon":0},{"id":"2539091262","title":"每周股票复盘:丽珠集团(000513)研发管线多领域推进,BD战略助力国际化","url":"https://stock-news.laohu8.com/highlight/detail?id=2539091262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539091262?lang=zh_cn&edition=full","pubTime":"2025-05-31 09:13","pubTimestamp":1748653990,"startTime":"0","endTime":"0","summary":"截至2025年5月30日收盘,丽珠集团报收于36.4元,较上周的36.65元下跌0.68%。本周,丽珠集团5月30日盘中最高价报36.95元。NS-041片是新一代KCNQ2/3激活剂,已完成临床I期,即将进入临床II期。重组抗人IL-17A/F人源化单克隆抗体注射液银屑病适应症已完成III期临床入组,计划于2025年内申报上市。此次收购战略意义主要是加强创新研发和全球布局协同发展,有助于公司快速融入当地市场,提升品牌的国际影响力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053100008520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0187","000513","BK0028"],"gpt_icon":0},{"id":"2538418803","title":"丽珠集团丽珠制药厂申请II类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2538418803","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538418803?lang=zh_cn&edition=full","pubTime":"2025-05-28 07:09","pubTimestamp":1748387363,"startTime":"0","endTime":"0","summary":"丽珠集团丽珠制药厂,成立于1989年,位于珠海市,是一家以从事医药制造业为主的企业。通过天眼查大数据分析,丽珠集团丽珠制药厂共对外投资了12家企业,参与招投标项目4300次,专利信息58条,此外企业还拥有行政许可464个。主要股东信息显示,丽珠集团丽珠制药厂由丽珠医药集团股份有限公司持股74.4573%、安滔发展有限公司持股24.57%、丽珠(澳门)有限公司持股0.9726%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/28070950698403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0028","000513","BK0187","BK0188"],"gpt_icon":0},{"id":"2538960480","title":"丽珠集团:5月26日接受机构调研,国联证券、华泰证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2538960480","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538960480?lang=zh_cn&edition=full","pubTime":"2025-05-27 10:40","pubTimestamp":1748313657,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年5月26日丽珠集团发布公告称公司于2025年5月26日接受机构调研,国联证券首席分析师 郑薇、华泰证券分析师 孙茗馨、中金医药分析师 宋歌、易方达基金基金经理 杨桢霄 研究员 王淑铖、泰康资产研究员 雷啸、华夏基金研究员 胥梦缘、广发基金研究员 姜冬青参与。参芪扶正注射液受益于医保后缀解限带来的市场扩容,销售有望持续攀升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052700010399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU1781817850.SGD","BK1147","601688","LU1934453819.USD","BK0276","LU1064130708.USD","LU1979443071.USD","LU1064131003.USD","BK0239","BK0188","BK1564","161027","BK0183","LU1580142542.USD","BK0028","LU2148510915.USD","06886","BK0187","000513","BK0012"],"gpt_icon":0},{"id":"2538755101","title":"丽珠集团:公司中药板块预计将实现稳健恢复性增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2538755101","media":"E公司","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538755101?lang=zh_cn&edition=full","pubTime":"2025-05-26 22:41","pubTimestamp":1748270478,"startTime":"0","endTime":"0","summary":"人民财讯5月26日电,丽珠集团在接受机构调研时表示,公司中药领域主要包括两大核心品种,即参芪扶正注射液和抗病毒颗粒。抗病毒颗粒在2023年高基数后逐步回归常态化增长,如果不考虑流感等突发因素,预计今年有小幅增长。参芪扶正注射液受益于医保后缀解限带来的市场扩容,销售有望持续攀升。总体而言,在政策环境稳定一致的情况下,公司中药板块预计将实现稳健恢复性增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052622411895032ef0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052622411895032ef0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","BK0187","BK0028","561510","000513"],"gpt_icon":0},{"id":"2537167911","title":"每周股票复盘:丽珠集团(000513)拟15.87亿收购越南IMP公司64.81%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2537167911","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537167911?lang=zh_cn&edition=full","pubTime":"2025-05-24 14:59","pubTimestamp":1748069947,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘,丽珠集团报收于36.65元,较上周的35.34元上涨3.71%。本周,丽珠集团5月23日盘中最高价报37.48元。5月19日盘中最低价报35.18元。关于拟收购越南IMP公司股权的公告丽珠医药集团股份有限公司拟通过境外全资附属公司LIAN SGP HOLDING PTE.LTD. 收购越南上市公司Imexpharm Corporation64.81%股份。交易金额为5,730,815,426,000越南盾。收购完成后,IMP将成为丽珠集团合并报表范围内的附属公司。此次交易不构成关联交易和重大资产重组,无需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400012729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000513","BK0188","BK0187","BK0028"],"gpt_icon":0},{"id":"2537077945","title":"健康元(600380.SH):控股子公司丽珠集团拟收购越南IMP公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2537077945","media":"格隆汇","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537077945?lang=zh_cn&edition=full","pubTime":"2025-05-22 20:07","pubTimestamp":1747915667,"startTime":"0","endTime":"0","summary":"格隆汇5月22日丨健康元(600380.SH)公布,公司控股子公司丽珠医药集团股份有限公司(简称“丽珠集团”)之全资附属公司LIANSGP \nHOLDINGPTE.LTD.(简称“LIAN \nSGP”)拟以5,730,815,426,000越南盾(折合约为人民币15.87亿元)收购越南上市公司Imexpharm Corporation \n64.81%股份。本次交易完成后,标的公司将成为本公司合并报表范围内的附属公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/22200750598343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0114","BK0077","BK0187","BK0046","000513","BK0188","BK0239","BK0028","600380"],"gpt_icon":0},{"id":"2537943110","title":"丽珠集团最新公告:拟15.87亿元收购越南IMP公司64.81%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2537943110","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537943110?lang=zh_cn&edition=full","pubTime":"2025-05-22 19:31","pubTimestamp":1747913478,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)公告称,公司境外全资附属公司LIAN SGP拟以约人民币15.87亿元收购越南上市公司IMP 64.81%股份。交易完成后,IMP将成为丽珠医药合并报表范围内的附属公司。交易不构成关联交易,亦不构成重大资产重组。交易尚需取得相关审批手续。IMP主营业务:IMP是一家越南领先的医药企业,主要从事药品的研发、生产和销售,其产品主要包括抗生素、心脑血管药物等,与本公司现有产品有较高协同性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200031739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0187","BK0028","000513"],"gpt_icon":0},{"id":"2537943105","title":"丽珠集团(000513.SZ)拟收购越南IMP公司64.81%股权 交易价格约15.87亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537943105","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537943105?lang=zh_cn&edition=full","pubTime":"2025-05-22 19:31","pubTimestamp":1747913469,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠集团 发布公告,公司境外全资附属公司LIAN SGP HOLDING PTE.LTD.于2025年5月22日与SK Investment Vina III Pte. Ltd.、Sunrise Kim Investment Joint Stock Company及KBA Investment Joint Stock Company签署了《Framework Agreement》,LIAN SGP拟收购卖方合计持有的越南上市公司Imexpharm Corporation64.81%股份。就本次交易拟支付的股权购买价格约为人民币15.87亿元,占公司最近一期经审计归属于公司股东净资产的11.45%。IMP是一家越南领先的医药企业,主要从事药品的研发、生产和销售,其产品主要包括抗生素、心脑血管药物等,与公司现有产品有较高协同性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1296524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0187","BK0028","000513"],"gpt_icon":0},{"id":"2536684571","title":"丽珠集团刘宁:累计投入超4亿用于节能减排及设备改造 在慢病防治、普惠医疗等领域公益性捐赠累计7000万","url":"https://stock-news.laohu8.com/highlight/detail?id=2536684571","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536684571?lang=zh_cn&edition=full","pubTime":"2025-05-19 20:32","pubTimestamp":1747657920,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索查看更多考评等级 专题:专题|深交所2025全球投资者大会:投资中国就是投资未来。 5月19日至20日,深交所2025全球投资者大会在深圳举行。丽珠集团董事会秘书刘宁分享了公司在环境、社会与公司治理领域的实践经验,强调以“长期主义”推动ESG与业务深度融合,并探索“产业+科技+ESG”的新质生产力路径。截至2024年,公司累计投入超4亿元用于节能减排及设备改造,温室气体排放量较基准年下降9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-05-19/doc-inexcfvs7523231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","000513","BK0188","BK0028","BK0239","159891"],"gpt_icon":0},{"id":"2533968946","title":"丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533968946","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533968946?lang=zh_cn&edition=full","pubTime":"2025-05-06 19:13","pubTimestamp":1746530008,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠集团(000513.SZ)发布公告,截至2025年4月30日,公司通过集中竞价交易方式回购了公司A股股份共计1131.89万股,占公司总股本的比例为1.24%,购买的最高价为人民币38.37元/股,最低价为人民币33.21元/股,已使用的资金总额为人民币4.07亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丽珠集团(000513.SZ)已累计回购股份1.24%股份 耗资约4.07亿元","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","000513","BK0187","BK0028"],"gpt_icon":0},{"id":"2531747281","title":"丽珠集团:4月29日接受机构调研,国信证券参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2531747281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531747281?lang=zh_cn&edition=full","pubTime":"2025-04-30 09:58","pubTimestamp":1745978288,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年4月29日丽珠集团发布公告称公司于2025年4月29日接受机构调研,国信证券首席分析师 陈曦炳 分析师 肖婧舒参与。抗病毒颗粒在 2023 年高基数后逐步归常态化增长,如果不考虑流感等突发因素,预计今年有小幅增长。参芪扶正注射液受益于医保后缀解限带来的市场扩容,销售有望持续攀升。2024年度,公司现金分红及股份购总金额占本年度公司归属于股东净利润的比例约为 88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000014814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0276","002736","BK0239","BK0028","BK0187","BK0183","BK0188"],"gpt_icon":0},{"id":"2529825578","title":"丽珠集团(000513.SZ)发布一季度业绩,归母净利润6.37亿元,同比增长4.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529825578","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529825578?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:21","pubTimestamp":1745400116,"startTime":"0","endTime":"0","summary":"智通财经APP讯,丽珠集团(000513.SZ)发布2025年一季度报告,第一季度,公司实现营业收入31.81亿元,同比下降1.92%。归属于上市公司股东的净利润6.37亿元,同比增长4.75%。归属于上市公司股东的扣除非经常性损益的净利润6.19亿元,同比增长4.82%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000513"],"gpt_icon":0},{"id":"2529228285","title":"【丽珠集团:副总裁杨代宏因工作调整原因辞职】丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529228285","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529228285?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:57","pubTimestamp":1745398645,"startTime":"0","endTime":"0","summary":"丽珠集团4月23日公告,公司董事会收到副总裁杨代宏的书面辞职报告,杨代宏因工作调整原因申请辞去公司副总裁职务,辞任后仍在公司担任其他职务,辞职申请自送达公司董事会之日起生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/23165749789708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0187","000513","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2529815676","title":"丽珠集团:公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2529815676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529815676?lang=zh_cn&edition=full","pubTime":"2025-04-21 09:06","pubTimestamp":1745197565,"startTime":"0","endTime":"0","summary":"证券之星消息,丽珠集团(000513)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问:公司身处珠海,请问“澳门横琴”新定位下的澳琴大健康产业合作对公司是利好吗?公司有采取什么举措去抓住这个政策红利吗?谢谢!丽珠集团回复:尊敬的投资者,您好!公司始终积极响应国家战略布局,密切关注粤港澳大湾区发展机遇。我们将持续深化与区域产业资源的协同合作,充分发挥自身在医药健康领域的专业优势,通过加强技术交流、优化资源配置等方式,主动把握政策导向下的发展契机。谢谢您的关注。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100002031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK1567","BK0028","BK0187","BK1507","00737","BK0239","BK1185"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752294081056,"stockEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0211},{"period":"3month","weight":0.112},{"period":"6month","weight":0.0656},{"period":"1year","weight":0.0644},{"period":"ytd","weight":0.0002}],"compareEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.0317},{"period":"3month","weight":0.084},{"period":"6month","weight":0.1078},{"period":"1year","weight":0.1817},{"period":"ytd","weight":0.0473}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"52348人(较上一季度减少0.90%)","perCapita":"11162股","listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","registeredCapital":"90410万元","survey":" 丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是注射用醋酸亮丙瑞林微球(贝依)、注射用尿促卵泡素(丽申宝)、注射用尿促性素(乐宝得)、艾普拉唑肠溶片及注射用艾普拉唑钠(壹丽安)、枸橼酸铋钾系列产品(丽珠得乐)、维三联(枸橼酸铋钾片/替硝唑片/克拉霉素片)、马来酸氟伏沙明片(瑞必乐)、盐酸哌罗匹隆片(康尔汀)、参芪扶正注射液、抗病毒颗粒。","listedPrice":6.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}